HbA1C: ITS EVALUATION AS A  SCREENING BIOMARKER OF DYSLIPIDEMIA IN DIABETES TYPE 2 PATIENTS

Sanjeev Dhakal; Uday N Singh; Subodh kumar

Volume : IV, Issue : X, October - 2015

HbA1C: ITS EVALUATION AS A SCREENING BIOMARKER OF DYSLIPIDEMIA IN DIABETES TYPE 2 PATIENTS

Sanjeev Dhakal, Uday N Singh, Subodh Kumar

Abstract :

Diabetes mellitus(DM) is a globally prevalent disease associated with hyperglycemia due to insulin deficiency or insensitivity or both. Hb1AC is used to assess blood sugar level over 3–4 months of the treatment period. DM type 2 patients have invariably abnormal lipid profile known as dyslipidemia. It is one of the important complications of diabetes mellitus. HbA1C can predict the status of the lipid profile or dyslipidemia in addition to blood sugar control. Several studies have found the very positive correlation between HbA1C and lipid profile .So, HbA1C might be used to predict dyslipidemia in DM type 2 patients.